EHA 2022

EHA 2022
June 09-12, 2022

The European Hematology Association (EHA) 2022.

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (5)

    Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 Phase 1b study results

    • Author(s): Sallman, D_
    • magrolimab
    • Oncology

    A Phase 3, Randomized Trial of Magrolimab in Combination With Venetoclax and Azacitidine in Previously Untreated Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy (ENHANCE-3)

    • Author(s): Daver, N
    • magrolimab
    • Oncology

    A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia

    • Author(s): Daver, N
    • magrolimab
    • Oncology

    Impact of magrolimab treatment in combination with azacitidine on red blood cells in higher-risk myelodysplastic syndrome (HR-MDS) patients

    • Author(s): Chen, J
    • magrolimab
    • Oncology

    Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results

    • Author(s): Daver, N
    • magrolimab
    • Oncology